Passage Bio Inc, Denali Therapeutics, and Prevail Therapeutics at Citi BioPharma Conference (Virtual) - Panel Transcript
All right. Hi, everyone. Thank you so much for joining the Citi's 15th Annual Biopharma Conference. My name is Neena Bitritto-Garg. I'm one of the mid-cap biotech analyst here at Citi.
So for our next panel, I'm very pleased to be joined by CEOs from Denali, Passage Bio and Prevail Therapeutics. So from Denali, we have Ryan Watts. From Passage Bio, we have Bruce Goldsmith. And from Prevail, we have Asa -- sorry, I apologize, Abeliovich. And we're going talk today about neurodegenerative diseases and some of the emerging and new kind of therapeutic modalities and mechanisms that companies are working on to combat neurodegenerative disease.
So to start off, I'd like to give everyone the opportunity to kind of just give a quick 1-minute intro kind of on the company, on -- and what you're working on right now. So if we want to start with -- maybe with Asa, and then we can go to Bruce and then Ryan.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |